Neuroligin 1: A splice site-specific ligand for β-neurexins  by Ichtchenko, Konstantin et al.
Cell, Vol. 81,435-443, May 5, 1995, Copyright © 1995 by Cell Press 
Neuroligin 1: A Splice Site-Specific Ligand 
for I -Neurexins 
Konstantin Ichtchenko, * Yutaka Hata, * Thai Nguyen, * 
Beate UIIrich,* Markus Messier,* Carolyn Moomaw,t 
and Thomas C. S0dhof*t 
• Department of Molecular Genetics 
tHoward Hughes Medical Institute 
The University of Texas Southwestern Medical Center 
at Dallas 
Dallas, Texas 75235 
Summary 
Neurexins are neuronal cell surface proteins with hun- 
dreds of isoforms generated by alternative splicing. 
Here we describe neuroligin 1, a neuronal cell surface 
protein that is enriched in synaptic plasma membranes 
and acts as a splice site-specific ligand for p-neur- 
exins. Neuroligin 1 binds to I~-neurexins only if they 
lack an insert in the alternatively spliced sequence of 
the G domain, but not if they contain an insert. The 
extracellular sequence of neuroligin 1 is composed of 
a catalytically inactive esterase domain homologous 
to acetylcholinesterase. In situ hybridization reveals 
that alternative splicing of neurexins at the site recog- 
nized by neuroligin 1 is highly regulated. These find- 
ings support a model whereby alternative splicing of 
neurexins creates a family of cell surface receptors 
that confers interactive specificity onto their resident 
neurons. 
Introduction 
some of the splice sites may have more than 10 variants. 
As a result, the total number of neurexins in brain probably 
exceeds 2000 forms (UIIrich et al., 1995). The variable 
sequences of the neurexins render them among the most 
polymorphic proteins known. 
The structures of the neurexins suggest a possible func- 
tion as cell surface receptors. Neurexins contain epider- 
mal growth factor-like sequences and domains homolo- 
gous to the G domain repeats of laminin A, indicating a 
function in cell-cell interactions. A 29 kDa protein copurify- 
ing with neurexin I~ in the ~-Iatrotoxin receptor has a struc- 
ture suggestive of a soluble ligand for neurexins (Ao G. 
Petrenko and T. C. S., unpublished ata). Putative ligands 
for neurexins could interact with all neurexins or with sub- 
sets of neurexins characterized by a specific pattern of 
alternative splicing. In the latter instance, alternative splic- 
ing would regulate the ligand specificity of each neurexin, 
implying the existence of a large number of different li- 
gands. 
Here we report the identification of a novel neuronal cell 
surface protein that binds to all three 13-neurexins but not 
to a-neurexins. The protein, called neuroligin 1 in antici- 
pation of additional ligands for neurexins, binds only to 
~-neurexins that lack an insert in the alternatively spliced 
sequence of the G domain, but not to I~-neurexins con- 
taining an insert. In situ hybridization reveals that the alter- 
native splicing of neurexins in the G domain is regulated 
in a region-specific fashion. These observations uggest 
that different splice versions of neurexins have different 
ligands and support a role for neurexins in neuronal speci- 
ficity. 
Neurexins are polymorphic cell surface proteins ex- 
pressed in neurons. They were discovered in the course 
of cloning the presynaptic receptor for ~-Iatrotoxin (Ush- 
karyov et al., 1992). Three genes encoding neurexins are 
known (named 1,2, and 3). Each neurexin gene has two 
independent promoters and generates two classes of 
mRNAs. The longer mRNAs encode a-neurexins and the 
shorter mRNAs 13-neurexins. This results in the synthesis 
of six principal neurexin isoforms, called neurexins is to 
11113, of which neurexin la corresponds to the high molecu- 
lar weight component of the a-latrotoxin receptor (Ushkar- 
yov et al., 1992, 1994). 
Neurexins are expressed at significant levels only in 
brain. The six isoforms are coexpressed in neurons and 
are distributed differentially in various brain regions. 
Groups of neurons exhibit different combinations of neu- 
rexins, resulting in a combinatorial specificity of neurexin 
expression that is generated by their cell type-specific 
transcription from six promoters in three genes (Uilrich et 
al., 1995). Another remarkable characteristic of neurexins 
is their evolutionarily conserved pattern of extensive alter- 
native splicing. ~-Neurexins hare five canonical sites of 
alternative splicing, the last two of which are also present 
in 13-neurexins. At most of these splice sites, two variants 
are observed (negative and positive inserts). However, 
Results 
Purification of Neuroligin 1 
To produce sufficient amounts of neurexins for biochemi- 
cal studies, we constructed a baculovirus vector encoding 
a secretecl form of neurexin 113. The protein was truncated 
in the middle of the O-linked sugar region before the trans- 
membrane region and fused to a His6sequence to facilitate 
purification. Recombinant neurexin 1~ was produced in 
Sf9 cells and purified to apparent homogeneity by a series 
of chromatography steps (see Experimental Procedures). 
Purified neurexin 113 was coupled to cyanogen bromide- 
activated Sepharose and used as an affinity matrix for 
total rat brain proteins solubilized in 3-[(3-cholamido- 
propyl)-dimethyl-am onio]-l-propanesulfonate (CHAPS) 
(Figure 1). 
Brain proteins were loaded onto the affinity column in 
the presence of Ca 2÷ at physiological salt concentrations 
and eluted with 1 M NaCI first in the presence of Ca 2+ 
(Figure 1, lanes 5-8) and then in the presence of EDTA 
(lanes 9 and 10). No specific binding protein was detected 
in the eluate containing Ca 2+. Elution with EDTA resulted 
in the purification of a single major protein of approxi- 
mately 116 kDa, which we named neuroligin 1 (asterisk in 
Figure 1). As a control, a column containing bovine serum 
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Figure 1. Purification of Neuroligin 1 by Affin- 
ity Chromatography on Immobilized Neu- 
rexin 113 
Neurexin 1~ and BSA were covalently coupled 
to cyanogen bromide-activated Sepharose. 
Total rat brain proteins solubilized in CHAPS 
(lane 1 ; L, loading material) were applied to the 
columns in the presence of Ca 2+, washed with 
loading buffer (lanes 2-4), and eluted first with 
1 M NaCI and Ca 2+ (lanes 5-8) and then with 1 
M NaCI and EDTA (lanes 9 and 10). Equivalent 
amounts of all fractions were analyzed by 
SDS-PAGE and Coomassie blue staining. 
Neuroligin 1 eluted from the neurexin 113 col- 
umn by EDTA is marked by an asterisk. Num- 
bers on the right indicate the size of molecular 
weight markers run in lanes labeled S. 
albumin (BSA) showed no bound protein (Figure 1, right). 
Furthermore, application of liver proteins to the neurexin 
113 column also failed to uncover specific binding proteins 
(data not shown). These experiments reveal the presence 
of a neurexin-binding protein in brain that tightly associ- 
ates with neurexin 113 in the presence of Ca 2+ and is purified 
from total brain in a single step by affinity chromatography. 
Structure of Neuroligin 1 
The brain protein eluted from immobilized neurexin 113 
was subjected to amino acid sequencing, cDNAs encod- 
ing neuroligin 1 were cloned based on the amino acid 
sequences obtained (Figure 2A). An initiator methionine 
codon was identified in the nucleotide sequence as the 
first ATG that is not closely followed by a stop codon. 
Translation of the nucleotide sequence predicts synthesis 
of an 843 amino acid protein. Sequence analysis using 
hydrophobicity plots (Kyte and Doolittle, 1982) reveals two 
regions of high hydrophobicity: a short region at the N-ter- 
minus and a 22 amino acid sequence close to the C-ter- 
minus. The N-terminal hydrophobic sequence has the 
characteristics of a signal peptide (yon Heijne, 1986) with 
a predicted cleavage site after residue 44. The C-terminal 
hydrophobic sequence has the size and hydrophobicity 
of a transmembrane region. 
Examination of multiple cDNA clones showed that two 
sequences of 27 bp and 60 bp are either present or absent, 
respectively (Figure 2A). Because these variations were 
found in multiple clones, it is likely that they represent 
alternative splicing events. Thus, neuroligin 1, like the neu- 
rexins, is subject to alternative splicing. 
All of the peptide sequences obtained from purified neu- 
roligin 1 were found in the translated cDNA sequence, 
suggesting that the cDNA encodes the protein purified. 
Purified neuroligin 1 migrates on SDS-polyacrylamide 
gels as a protein of approximately 116 kDa, whereas the 
cDNA sequence predicts ynthesis of a 95 kDa protein. 
The fuzzy appearance of purified neuroligin I on SDS gels 
(see Figure 1) suggests that it may be glycosylated. The 
structure of neuroligin 1 contains multiple scattered con- 
sensus sequences for N-linked glycosylation. In addition, 
a cluster of serine and threonine residues that may serve 
as O-linked sugar acceptor sites is present N-terminal to 
the transmembrane region (Figure 2A). To test whether 
neuroligin 1 is N-glycosylated, O-glycosylated, or both, we 
digested it with a series of glycohydrolases (neuramini- 
dase, N-glycosidase F, and O-glycanase) and analyzed its 
size by immunoblotting. These experiments demonstrated 
that neuroligin I contains both N-linked and O-linked sug- 
ars, with the sugar residues accounting for the size differ- 
ence between native neuroligin 1 and its primary transla- 
tion product (data not shown). The O-glycosylation of 
neuroligin 1 may create a carbohydrate-rich domain just 
outside its transmembrane region, similar to O-linked gly- 
cosylation cassettes in other cell surface receptors. 
The presence of a signal sequence and of a single trans- 
membrane region in neuroligin 1 suggests that neuroligin 
1 is a type 1 membrane protein with an extracellular N-ter- 
minus and an intracellular C-terminus. A domain model 
for neuroligin 1 is proposed in Figure 2B based on this 
transmembrane topology. According to this model, neurol- 
igin 1 contains an extracellular sequence of 651 amino 
acids (after signal peptide cleavage and including both 
alternatively spliced sequences) and a cytoplasmic region 
of 126 amino acids. The domain model of neuroligin 1 is 
supported by the observed glycosylation of neuroligin 1 
and the presence of an O-glycosylation cassette N-ter- 
minal to the membrane-spanning region. In addition, a 
cluster of positively charged amino acids flanks the trans- 
membrane region on the intracellular side, as is typical 
for stop-transfer sequences (von Heijne and Gavel, 1988). 
Finally, the N-terminal esterase homology domain of neu- 
roligin 1 (see below) further supports the assignment of 
the N-terminus to the extracellular space. 
Neuroligin 1 Has an Esteraee-like Domain 
Data base searches revealed a significant homology of 
almost the entire extracellular domain of neuroligin 1 with 
members of the esterase protein family. This diverse fam- 
ily of proteins includes true esterases such as acetylcholin- 
esterase and carboxylesterase, as well as nonesterase 
proteins such as thyroglobulin and neurotactin (de la Es- 
calera et al., 1990; Hortsch et al., 1990; Takagi et al., 
1988). An alignment of the neuroligin 1 sequence with 
sequences of selected esterase domain proteins shows 
that the homology of neuroligin 1 to other members of this 
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Figure 2. Structure of Neuroligin 1 
(A) Amino acid sequence of rat neuroligin 1 deduced from cDNA 
clones. Sequences determined of tryptic peptides from purified neurol- 
igin 1 are underlined, and the putative signal sequence and transmem- 
brane region are double underlined. The two alternatively spliced se- 
quences are boxed. Asparagine resides of N-linked glycosylation 
consensus sequences and clustered serine and threonine residues 
close to the transmembrane region that serve as putative O-linked 
glycosylation sites are shown on a black background. The cytoplasmic 
domain contains two copies of a 6-residue repeat (MTPNTI/MIPNTI; 
residues 796-808). 
(B) Domain structure of neuroligin 1. Neuroligin 1 is composed of 
N-terminal extracellular domains that include an esterase domain and 
a putative O-linked glycosylation domain, a single transmembrane r - 
gion (TMR), and a C-terminal cytoplasmic sequence. The putative 
N-terminal signal peptide is labeled SP. The two alternatively spliced 
sequences in the esterase domain are labeled A and B and are cross- 
hatched. The rectangular lines below the bar denote proposed disui- 
fide loops based on the crystal structure of ace- 
tylcholinesterase (Sussman et al., 1991). 
(C) Sequence alignment of neuroligin 1 with 
five representative members of the esterase 
domain family. Sequences are identified on the 
left and numbered on the right. Abbreviations: 
NL, neuroligin; Bal, rat bile acid-activated es- 
terase (Han et al., 1987); Ace, Torpedo acetyl- 
cholinesterase (Sikorac et al., 1987); Car, rat 
carboxylesterase ES-10 (Robbi et al., 1999); 
Thy, rat thyroglobulin (Di Lauro et al., 1985); 
Neu, Drosophila neurotactin (de la Escalera et 
al., 1990; Hortsch et al., 1990). Residues identi- 
cal in at least 50% of the sequences are shown 
on a black background. Hyphens indicate 
spaces. Note that the active site serine (corre- 
sponding to residue 281 in neuroflgin 1) is sub- 
stituted for an inactive residue in neuroligin 1, 
neurotactin, and thyroglobulin. Alternatively 
spliced segments of neuroligin 1 are boxed. 
family is uniformly distributed over the entire length of the 
domain (Figure 2C). As it is in thyroglobulin and neurotac- 
tin, the serine residue at the active site in neuroligin 1 is 
replaced by an inert amino acid, suggesting that neuroligin 
1 is not a catalytically active esterase. Of the six disulfide- 
bonded cysteine residues in acetylcholinesterase, four are 
conserved in all members and al low a tentative assign- 
ment of disulfide bonds in neuroligin 1 (Figure 2B). The 
alternatively spliced segments of neuroligin 1 map to loops 
in the crystal structure of acetylchol inesterase (Sussman 
et ai., 1991), indicating that these sequences are accom- 
modated in the tertiary structure of neuroligin 1 as ex- 
tended surface loops. Interestingly, the longer alterna- 
tively spliced sequence contains two cysteines and may 
form a disulf ide-bonded ring (Figure 2B). 
A quantitative assessment of the degree of relatedness 
of neuroligin 1 to other members of the esterase domain 
family reveals that it is similarly related to all members 
(32%-36% sequence identity), with small differences 
among proteins. Neurotactin is the only member  of the 
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Figure 3. Brain-Specific Expression and Subcellular Localization of 
Neuroligin 1 
(A) Tissue distribution of neuroligin 1 expression. A blot containing 
total RNA from the indicated rat tissues was hybridized with a uniformly 
labeled neuroligin 1 probe and exposed to film at -70°C for 1 hr (top). 
The same blot was rehybridized with GAPDH and cyclephilin probes 
to control for RNA loads (bottom). Numbers on the left indicated posi- 
tions of molecular weight markers (in kilobases). 
(B) Subcellular f actionation of brain. Crude synaptosomes were iso- 
lated by differential centrifugation (P2), lysed hypoosmotically, and 
separated into fractions enriched in heavy membranes (LP1), in SPMs, 
in synaptic vesicles (LP2), and in cytosol (LS2). Equal aliquots of each 
fraction were immunoblotted using antibodies against the indicated 
proteins. Numbers on the left indicate positions of molecular weight 
markers (in kilobases). 
esterase family currently listed in the data bases that, in 
addition to neuroligin 1, contains a transmem brane region, 
but neuroligin is less related to neurotactin (27% identity) 
than to other esterase proteins. Moreover, neurotactin is 
a type 2 membrane protein with an N-terminal transmem- 
brane region whereas neuroligin 1 is a type 1 membrane 
protein with a C-terminal transmembrane region. Together 
these findings suggest that neuroligin 1 is not the mamma- 
lian homolog of neurotactin. 
Expression of NeuroUgin 1 in Brain 
RNA blotting experiments were performed to determine 
the site of expression of neuroligin 1. A single hybridizing 
mRNA of approximately 6 kb was observed only in brain 
(Figure 3A). No signal was detected in other tissues, even 
after prolonged exposure. In immunoblotting experiments 
with proteins from a variety of tissues, neuroligin 1 could 
also only be detected in brain (data not shown). In situ 
hybridization experiments using a specific oligonucleotide 
complementary to the neuroligin 1 mRNA showed a neu- 
ronal pattern of expression with weak hybridization to all 
brain areas (data not shown). 
Enrichment of Neuroligin 1 in Synaptic 
Plasma Membranes 
Subcellular fractionation of brain demonstrated that neu- 
roligin 1 is enriched in synaptosomes similar to the post- 
synaptic density protein PSD95 (P2 in Figure 3B). Subfrac- 
tionations of the synaptosomes into synaptic vesicles 
(LP2), cytosol (LS2), and synaptic plasma membranes 
(SPMs) show that neuroligin 1 also copurifies with PSD95 
on SPMs. Both proteins are completely absent from synap- 
tic vesicles. SPMs contain both pre- and postsynaptic ele- 
ments and docked synaptic vesicles, resulting in the en- 
richment of most synaptic vesicle proteins in this fraction 
in addition to their presence in the synaptic vesicle fraction 
(except for rab3A, which dissociates probably during dock- 
ing; Fischer von Mollard et al., 1991). 
Splice Site-Specific Binding of Neuroligin 1 
to p-Neurexins 
Neuroligin 1 was purified in a single step from total brain 
by affinity chromatography on immobilized neurexin 113 
containing a Hiss-tagged C-terminus. To exclude potential 
artifacts caused by the method of immobilization of neu- 
rexin 115 or by the presence of a Hiss sequence and to 
examine the binding specificity of neuroligin 1 to different 
neurexins, we produced a series of recombinant neu- 
rexin-immunoglobulin G (IgG) fusion proteins and tested 
their ability to bind neuroligin 1 (Figure 4). 
We produced 11 IgG fusion proteins to examine the 
binding specificity of neuroligin 1: one control IgG fusion 
protein consisting of the signal peptide of neurexin 1~ 
fused to IgG (Figure 4, IGN control) and 10 neurexin-lgG 
fusion proteins in which the extracellular domains of ~- or 
13-neurexins are fused to the Fc domain of human IgG after 
splice site 4 in the last G domain repeat (diagrammed in 
Figure 4A). Neurexins 11~ and 215 were expressed with or 
without an insert in the alternatively spliced sequence 4 
in the G domain (referred to as insert-negative and insert- 
positive 15-neurexins; IGN 115-1, 115-3, 213.3, and 213-4 in 
Figure 4) and neurexin 11113 without an insert at this site 
(IGN 313-1 in Figure 4). In addition, four different insert- 
negative and insert-positive neurexin l~- IgG fusion pro- 
teins were examined. 
Neuroligin 1 binding to different neurexin-lgG fusion 
proteins was studied by testing the ability of the proteins to 
affinity purify neuroligin 1 from brain homogenates. Affinity 
chromatography on insert-negative 13-neurexins resulted 
in the isolation of a family of closely spaced proteins of 
110-116 kDa as the only proteins purified (see Coomassie 
blue-stained gel in top panel of Figure 4B). Binding of 
these proteins was Ca 2÷ dependent; no protein band was 
detected in the eluates from insert-positive 13-neurexins. 
Immunoblotting confirmed that neuroligin 1 was a major 
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Figure 4. Neuroligin 1 Binding to ~-Neurexin-lgG Fusion Proteins 
(A) Structures of neurexin-lgG fusion proteins. IgG fusion proteins 
contain N-termini composed ither of the extracellular domains of 
~-neurexins (e-neurexin IG) or of the extracellular domains of ~-neu- 
rexins (6-neurexin IG) or of the neurexin 1 cz signal peptide only (control 
IG). The first four of the five canonical sites of alternative splicing in 
J3-neurexins (UIIrich et al., 1995) are indicated by arrows and labeled 
1-4. Only the N-terminal sp!ice site of 6-neurexins in the G domain 
(site 4) is present in the neurexin 113 constructs. The IgG domain is 
shown as a closed box, and different neurexin domains are shown as 
hatched boxes (SP, signal peptide; EGF, epidermal growth factor-like 
domain). 
(B) Specificity of neuroligin 1 binding to I~-neurexins with or without 
inserts in the G domain splice site. Control IgG fusion protein (lane 
1) or IgG fusion proteins of neurexins 16, 213, and 317, without or with 
a splice site insert in the G domain repeat (lanes 2-6; for neurexin 
36, only the variant lacking an insert was analyzed) were used as 
affinity matrices for protein purification from total rat brain homoge- 
nate. The top panel depicts a Coomassie blue-stained gel of the elu- 
component of the eluate from all insert-negative 13-neu- 
rexins, although the eluates from the different ~-neurexins 
are not stained equally by neuroligin antibodies (Figure 
4B, middle). The purification of multiple protein bands that 
are not equally immunoreactive with neuroligin 1 antibod- 
ies indicates that there may be additional forms of neuroli- 
gin. Comparison of the Coomassie blue stain of the eluate 
with that of the affinity matrix (Figure 4B, top and bottom) 
suggests that neuroligin 1 binding to 13-neurexins is stoi- 
chiometric. All of the binding observed is Ca 2÷ dependent 
(data not shown), in contrast with the binding of brain neu- 
roligin 1 to insert-negative 13-neurexins, no binding could 
be detected to insert-negative or insert-positive ~-neurex- 
ins (data not shown). Together these results suggest that 
neuroligin 1 binds with high affinity only to 13-neurexins 
that lack an insert in the alternatively spliced sequence 
in the G domain. 
Recombinant NeuroUgin 1 Reproduces the Binding 
Specificity of Native Neuroligin 
To determine whether neuroligin 1 binds directly to ~-neu- 
rexins or requires brain-specific proteins for binding, we 
used transfection to express neuroligin 1 in COS cells. 
A single 116 kDa immunoreactive band was detected in 
transfected COS cells, but not in control cells (data not 
shown). Membrane proteins from transfected COS ceils 
were solubilized in CHAPS and chrornatographed on im- 
mobilized neurexin- lgG fusion proteins as described 
above. As observed for brain homogenates, recombinant 
neuroligin 1 only bound to insert-negative J3-neurexins but 
not to insert-positive l~-neurexins (Figure 4C). Further- 
more, no binding of recombinant neuroligin 1 to J3-neu- 
rexins was detected (data not shown). Testing of multiple 
neuroligin 1 proteins that contain or lack inserts in the two 
alternatively spliced regions of neuroligin 1 showed that 
alternative splicing has no apparent effect on neurexin 
binding. These experiments confirm that we cloned a func- 
tionally active ligand for l~-neurexins that only reacts with 
~-neurexins lacking an insert in the G domain splice site. 
Presence of Native Neurexin-Neurol igin 
Complexes in Brain 
Immunoprecipitations were performed to examine whether 
brain contains a complex of endogenous neurexins and 
neuroligin 1. Neurexins were immunoprecipitated from 
brain in the presence of Ca 2÷ using an antibody that reacts 
with the C-terminus of both a- and I~-neurexins. This anti- 
body was shown previously to immunoprecipitate c~-Iatro- 
ates to demonstrate quantitative isolation of neuroligin 1 (arrows) by 
all three insert-negative 6-neurexins but not by insert-positive 6-neu- 
rexins. The middle panel shows an immunoblot f the eluates with an 
antibody to neuroligin 1. The bottom panel shows a Coomassie blue- 
stained gel of the IgG fusion proteins used (indicated by arrowheads). 
(C) Affinity purification f neuroligin 1 expressed in COS cells by differ- 
ent ~-neurexin-lgG fusion proteins, COS cells expressing transfected 
neuroligin 1 (lane 1)were solubilized in CHAPS and chromatographed 
on immobilized neurexin-lgG fusion proteins. Equivalent amounts of 
all fractions were analyzed by immunoblotting for neu roligin 1. Molecu- 
lar weight standards are shown on the right. 
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Figure 5. Coimmunoprecipitation f Neuroligin 1 with Naurexins from 
Rat Brain 
Total rat brain homogenates in CHAPS (lane 1) were incubated in the 
presence of Ca 2÷ with protein A beads containing oantibodies (lane 
2), with preimmune serum (lane 3), or with anti-neurexin antibodies 
(lane 3). Immunoprecipitates were eluted with EDTA and analyzed by 
immunoblotting for neuroligin 1. Only neurexin antibodies coimmuno- 
precipitate neuroligin 1, with the upper of the two bands observed 
corresponding to the size of neuroligin 1 expressed in COS cells; the 
lower band may be a proteolytic product or may correspond to a related 
protein. The slower migration on the gel of neuroligin I from the immu- 
noprecipitate than from brain is probably due to the high levels of IgG 
in this sample. Numbers on the left indicate positions of molecular 
weight markers. 
toxin-binding sites potently from rat brain (Hata et al., 
1993a). Immunoprecipitates were washed with high salt 
and eluted with EGTA. As controls, protein A beads con- 
taining no antibodies or preimmune serum were processed 
identically. Immunoblotting of the eluates demonstrated 
that neuroligin 1 could be eluted from the immunoprecipi- 
tates obtained with the neurexin antibody but not from 
control immunoprecipitates (Figure 5). Two bands are ob- 
served similar to the purification of neuroligin 1 using neu- 
rexin- lgG fusion proteins, possibly because of proteolytic 
degradation or owing to the presence of multiple forms 
of neuroligin. Thus, native brain homogenates contain a 
complex between endogenous neurexins and neuroligin 1. 
Primary Hippocampal Neurons Bind 
Recombinant p-Neurexins 
To determine whether neuroligin 1 is a cell surface protein, 
we incubated transfected COS cells with ~-neurexin-lgG 
fusion proteins. Only COS cells expressing neuroligin 1 
bound insert.negative neurexin 113 at 4°C and 37°C and 
internalized it at 37°C during a 24 hr incubation. In con- 
trast, the control IgG fusion protein did not bind (data not 
shown), This suggests that neuroligin I on the cell surface 
can bind 13-neurexins, suggesting that developing neurons 
in culture may also expose binding sites. Therefore, we 
incubated primary hippocam pal neurons from rat embryos 
with an insert-negative neurexin ll3-1gG fusion protein. At 
4°C, specific binding of neurexin 11~ in dotlike structures 
was observed, and longer incubations at 37°C resulted 
in their internalization (Figure 6; data not shown). Binding 
and internalization of 13-neurexins were present all over 
the cell surface but concentrated on neurites. 
Differential Expression of Neurexin Splice 
Forms in Brain 
The specificity of neuroligin 1 binding to only one splice 
form of 13-neurexins uggests a regulatory function for al- 
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Figure 6. Binding of Neurexin ll3-1gG Fusion Protein to the Cell Sur- 
face of Cultured Hippocampal Neurons 
Hippocampal neurons in primary culture we  incubated with an insert- 
negative neurexin 1.15 fusion protein produced in transfected COS cells 
(A and B) or with corresponding material from control-transfected COS 
cells ((3 and D), fixed, and double labeled byimmunofluorescence for 
human IgG to stain the I}-neurexin fusion protein (A and C) and for 
MAP2 as a neuronal marker (B and D). Small arrows in (A) point to 
neurexin 11~ dots of different sizes on neurites, large arrows t  cell 
bodies, and open arrows toartifactual precipitates on the polylysine 
substrate used for the culture. Dots in the upper right quadrant in (A)
belong to the neurites of a different neuron. Experiments using control 
IgG fusion proteins (Figure 4A) gave results similar to those shown in 
(C) and (D). ((3) and (D) had exactly the same exposure times during 
photography as (A) and (B), respectively. Magnification, 118 x. 
ternative splicing of neurexins in cell-cell interactions. 
This raises the question whether alternative splicing at 
the corresponding site of the neurexins is regulated. To 
address this, we investigated the distribution of alternative 
splicing of neurexin mRNAs in rat brain by in situ hybridiza- 
tion using specific oligonucleotides. Neurexins 1 and 2 
had to be analyzed together in these experiments because 
their sequence similarity in this region did not allow synthe- 
sis of isoform-specific probes. 
The hybridization patterns of splice site-specific oligo- 
nucleotides with rat brain sections reveal major differ- 
ences in the regional distributions of spliced sequences 
(Figure 7). For example, the striatum, substantia nigra, 
and cerebellar nuclei exhibit much higher levels of insert- 
positive than of insert-negative neurexin 1 and 2 mRNAs 
whereas the CA3 region of the hippocampus and the cere- 
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Figure 7. Differential Distribution i Rat Brain of Neurexin Splice Vari- 
ants in the G Domain Repeat 
Rat brain sections were hybridized with oligonucleotides specific for 
the insert-negative and insert-positive splice variants of neurexins 1 
and 2 (NI + II) or 3 (NIII) at splice site 4, which regulates neurofigin 1
binding. Pictures show film autoradiograms exposed 3-6 weeks. Note 
the distinct differential expression of splice variants in areas such as 
the cerebellar nuclei (CN), the striatum (S), the substantia nigra (SN), 
the dentate gyrus (DG), and the CA3 region (CA3) of the hippocampal 
formation. 
bral cortex show the opposite pattern. For neurexin 3, the 
most striking difference in distribution is observed in the 
hippocampus, where the pyramidal neurons ofCA1 to CA4 
have no detectable insert-positive mRNA but express high 
levels of insert-negative mRNA. Thus, alternative splicing 
at the site that regulates neuroligin 1 binding to 13-neu- 
rexins is highly regulated. 
Discuss ion  
Neurexins are neuronal cell surface proteins character- 
ized by a high degree of polymorphism that results from 
an unusually diverse pattern of alternative splicing. Using 
affinity chromatography on immobilized neurexin 11{3, we 
have isolated a protein named neuroligin 1 that tightly 
binds to 13-neurexins but not to a-neurexins. Neuroligin 1 
interacts with all three 13-neurexins, but it only binds to 
those 13-neurexins that lack an insert in the alternatively 
spliced sequence in the G domain. Cloning of neuroligin 
1 revealed that it constitutes a novel type 1 membrane 
protein with a large extracellular domain, a single trans- 
membrane region, and a cytoplasmic tail. Data base 
searches showed that neuroligin 1 belongs to a class of 
proteins referred to as esterase domain proteins because 
of their homology to esterases such as acetylcholinester- 
ase, although neuroligin 1 lacks the active site serine resi- 
due required for catalytic activity. Thus, a ligand for !3-neu- 
rexins was discovered that only binds to one splice form 
of 13-neurexins and is itself an intrinsic membrane protein 
on the neuronal cell surface. 
Based on these data, we would like to propose that sur- 
face expression of neuroligin 1 and 13-neurexins on neu- 
rons leads to tight interactions between these neurons. 
This recognition event is dependent on the alternative 
splicing of the 13-neurexins in the G domain, which exhibits 
a distinct differential distribution in brain. (z-Neurexins do 
not bind, although they also contain the site of alternative 
splicing that regulates l~-neu rexin binding, presumably be- 
cause the N-terminal sequence unique to 13-neurexins is 
involved in neuroligin 1 binding. Therefore, recognition 
among neurons mediated by the neurexin-neuroligin i - 
teraction is dependent on transcriptional regulation (ex- 
pression of different 13-neurexins that are heterogeneously 
distributed) and regulation of alternative splicing. This 
demonstrates an interaction between intrinsic membrane 
proteins that is regulated by alternative splicing. Interest- 
ingly, agrin, a secreted protein that contains G domains, 
is also alternatively spliced at two positions next to or in 
a G domain (Rupp et al., 1991 ; Ruegg et al., 1992). Alterna- 
tive splicing of agrin regulates its biologic activity (Ruegg 
et al., 1992; Ferns et al., 1993), but no splice site-specific 
receptor for agrin has been identified. 
The model for the function of 13-neurexins and neuroligin 
1 is supported by the following findings. First, neurexins 
and neuroligin 1 are both neuronal cell surface proteins. 
Second, neuroligin 1 only binds to one of two splice vari- 
ants of 13-neurexins in the G domain, a domain that also 
serves to mediate binding to cells in other proteins (Gehl- 
sen et al., 1992). Third, the alternatively spliced sequence 
recognized by neurotogin 1 is differentially distributed in 
brain. Fourth, a native complex between endogenous neu- 
rexins and neuroligin 1 is present in brain. (z- and 13-neu- 
rexins are expressed in many splice variants in brain that 
may give rise to more than 2000 proteins (UIIrich et al., 
1995). Neuroligin 1 only binds to one splice variant of 
~-neurexins that is present in only half of the 13-neurexins. 
Thus, neuroligin 1 is a ligand only for a small fraction of 
neurexins. Major additional igands for neurexins remain 
to be discovered that could collaborate to determine the 
specifity of interactions between neurons. 
The exact subcellular Iocalizations of neurexins and 
neuroligin 1 and the place of their interaction are unknown. 
It is tempting to speculate that they may mediate interac- 
tions between neurons at the synapse. This hypothesis is 
suggested by the localization of neurexin 1 to synapses, 
the homology of neuroligin 1 to synaptic acetylcholinester- 
ase, its enrichment in SPMs together with a postsynaptic 
density marker, and the Ca 2+ dependence of neurexin- 
neuroligin binding since synaptic structures are depen- 
dent on extracellular Ca 2+. It would imply that neurexins 
are localized to the presynaptic terminal and neuroligin 1 
to the postsynaptic side and that their interaction contri- 
butes to the organization of the synapse. The regulated 
expression of the alternatively spliced variant of 13-neu- 
rexins that binds neuroligin 1 suggests that the 13-neu- 
rexin-neuroligin 1 interaction may stabilize subclasses of 
synapses. The tight interaction of neuroligin 1 with l~-neu- 
rexins could form a stable scaffold for other interactions, 
thereby increasing the specificity of interactions or speci- 
fying a defined sequence of interactions. 
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Experimental Procedures 
Production of Recombinant Neurexins by Expression 
in Baculovirus and in COS Cells 
Neurexin 115 was cloned into the baculovirus expression vector 
pVL1392 (Invitrogen) by fusing its extracellular domains at the Sail 
site (corresponding to residue 1339 in neurexin la; Ushkaryov et al., 
1992) to a His6 sequence followed by a stop codon. Recombinant 
baculoviruses were produced (Summers and Smith, 1987) and used 
to infect Sf9 cells cultured in serum-free medium (SF900-11, GIBCO). 
Recombinant neurexin 19 was purified from the culture medium 72 
hr after infection by precipitation with 75% ammonium sulfate, by chro- 
matography on concanavalin A-Sepharose, and by chromatography 
on NF÷/NTA-agarose (Qiagen). Neurexin 113 was eluted by 0.25 M 
imidazole, dialyzed, and purified further by anion exchange chroma- 
tography on MonoQ and by gel filtration on Superdex-2O0, after which 
the protein was electrophoretically pure (yield of 10 rag/I). Purified 
neurexin 1~ was coupled to cyanogen bromide-activated Sepharose 
4B (Pharmacia) with 5 g of protein per liter of gel. Construction of 
~-neurexin-lgG and [5-neurexin-lgG fusion protein constructs and pro- 
duction of protein by transfection in COS cells were performed as 
described by Ushkaryov et al. (1994). 
Purification of Neuroligin 1 and Protein Sequencing 
Rat brains (60 g) were homogenized in 0.25 1 of buffer A (0.1 M NaCI, 
4 mM KCI, 5 mM CaCI2, 2.5 mM EDTA, 20 mM NaHCO3, 20 mM Tris- 
HCI [pH 7.5], 0.1 g/I PMSF, 1 mg/I leupeptin, 1 mg/I pepstatin A, and 
1 mg/I aprotinin). CHAPS was added to a final concentration of 2% 
(w/v) and dissolved under stirring at 4°C for 1 hr. Insoluble material 
was removed by low speed (2,000 x g) and high speed (80,000 x g) 
centrifugations. The supernatant (approximately 220 ml) was diluted 
with an equal volume of buffer A and chromatographed on the affinity 
columns (neurexin llB-Hise coupled to Sepharose, BSA coupled to 
Sepharose, and different IgG proteins attached to protein A-Sepha- 
rose) preequilibrated in buffer A containing 0.80/o CHAPS. Columns 
were eluted with buffer B (1 M NaCI, 4 mM KCI, 5 mM CaCI2, 2.5 mM 
EDTA, 20 rnM NaHCO3, 20 mM Tris-HCI [pH 7.5], 0.8% CHAPS) 
followed by buffer B containing 25 mM EDTA and 25 mM EGTA. Sam- 
ples were analyzed by SDS-polyac rylamide gel electrophoresis (SDS- 
PAGE) and by silver staining, Coomassie blue staining, and immu- 
noblotting. For amino acid sequencing, neuroligin 1 was separated 
on an SDS gel, blotted, and digested with trypsin (Hata et al., 1993b). 
Sequences were obtained after high pressure liquid chromatography 
purification of tryptic fragments on an ABI amino acid sequencer. 
cDNA Cloning, Construction of Expression Vectors, 
and COS Cell Expression of Neuroligin 
The longest peptide sequence from neuroligin 1 (ELN NEILVPVIQFLG- 
VPYAAPPT) was chosen to design short oligonucleotides complemen- 
tary to its ends. Sequences, with letters in parentheses indicating 
redundant positions, are as follows: CGCGAGCTCAA(C,T)AA (C,T)G- 
A(G,A)AT(A,T,C)(T,C)T and GGGCTGCAGCNGC(A,G)TANGGNAC- 
NCC. The cDNA sequence encoding the peptide was cloned by PCR 
using single-stranded rat brain cDNA as a template and sequenced. 
Multiple related sequences were obtained, indicating the possibility 
of multiple neuroligins. An oligonucleotide was designed (CGCCCAT- 
GGTCAATAACGAGATACTGGGCCCGGTCGTGCAGTTCTTGG) on 
the basis of the PCR sequence most closely related to the peptide 
sequence and used in a second set of PCRs with a fourth oligonucleo- 
tide based on the peptide sequence PYKELVDQ (sequence, TGCA- 
GATCTTGGTCCAC[C,T]A[G,A][T,C]TC[C,T]TT[A,G]TANGG). A 0.8 
kb product from this PCR encoding the correct sequence was used 
for screening rat cDNA libraries. Of the clones isolated, 19 were char- 
acterized by DNA sequencing, and six were fully sequenced. Expres- 
sion vectors were created by subcloning two cDNA clones that either 
contain or lack the the alternatively spliced sequences (pNLig37a and 
pNLig62b) into pCMV-based expression vectors and transfected into 
COS cells (Ushkaryov et al., 1994). 
Antibodies and ImmunoprecipitaUons 
Antibodies were raised against a synthetic peptide from the C-terminus 
of neuroligin 1 (sequence, CHPHPHPHSHSTTRV) coupled to keyhole 
limpet hemocyanin (Johnston et al., 1989). Aliquots (5 ml) of CHAPS- 
solubilized rat brain homogenates prepared as described above were 
incubated for 2 hr at 4°C with 20 ~1 of preimmune serum, anti-neurexin 
antibodies (Hata et al., 1993a), or no additions. After adding 50 p~l of 
protein A-Sepharose (Pharmacia) preequilibrated with buffer A con- 
taining 1% CHAPS and 5 g/I BSA, samples were incubated for 14 hr. 
Beads were washed twice in buffer A containing 1% CHAPS and in 
buffer S and eluted in buffer B containing 25 mM EDTA and 25 mM 
EGTA. The eluate was precipitated with TCA and analyzed by SDS- 
• PAGE and immunoblotting. 
~-Neurexin-lgG Binding to Transfected COS Cells 
and Primary Hippocampal Neurons 
Primary hippocampal neurons were cultured on polylysine-coated cov- 
erslipe (Banker and Cowan, 1977), Coverslips after 4-10 days in vitro 
were transferred to 12-well dishes, IgGs and IgG fusion proteins puri- 
fied from the media of COS cells transfected with control DNA or with 
neurexin 1~ and control IgG fusion protein vectors were added to the 
culture medium. After 2 or 24 hr incubation at 4°C or 37°C, coverslips 
were rinsed with medium, fixed in 4% paraformaldehyde, 0.1 M phos- 
phate buffer [pH 7.4], treated with 0.3% Triton X-100 (5 min), and 
blocked in 2% goat serum (1 hr). Cells were stained with a mouse 
monoclonal antibody against MAP2 (Sternberger)followed by fluores- 
cein-conjugated goat anti-mouse antibodies and rhodamine-labeled 
goat anti-h u man IgG. Transfected COS cells were transferred to polyly- 
sine-coated coverslips 1 day after transfection, cultured for 2 days 
more, and then treated the same way as the hippocampal cultures, 
In Situ Hybridizations 
In situ hybridizations were performed (UIIrich et al., 1995) using rat 
brain cryostat sections and 3sS-labeled oligonucleotides of the follow- 
ing sequences: insert-negative neurexins 1 and 2, GAAGATTGTGAG- 
CTGACGCCCTGCAGGGTATCGTTCGATGAC; insert-positive neu- 
rexins 1 and 2, ACTCGACCAAGTCGATATGGAATTCGCTGTCTA- 
GCAATCGCCAG; insert-negative neurexin 3, GAAGATGGTT AGCT- 
GCCGGCCTGTAGGATAATGCTCAI-rCAC; insert-positive neurexin 
3, CAGGCCGA'I-I-ATATI-IGAAGGGGAt t t tCTGtt/tACCATI-I-GG; 
and neuroligin 1, CTTCTGCAGGCATFCTACTAACTCTACTGTATCT- 
GACACA. For controls, all hybridizations were performed with a 50- 
to 100-fold excess of unlabeled oligonucleotide to displace specific 
signals, resulting in a complete abolition of signal. 
Miscellaneous Procedures 
Subcellular fractionation of fresh rat brains was performed as de- 
scribed previously (Jones and Matus, 1974). SDS-PAGE, iromunoblot- 
ting, and silver staining were performed using standard procedures 
and antibodies described previously (Johnston et al., 1989; Ushkaryov 
et al., 1992). RNA blots were purchased from Clontech and hybridized 
with uniformly labeled cDNA probes (Ushkaryov et al., 1992). 
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